Better Health for All

- $11.4 billion invested in R&D
- 105,000 patients provided access to HIV treatment
- 106,000 patients provided access to MDR-TB treatment
- $37 million donated for disaster relief to support our communities
- 75,000 health workers educated in 54 countries

Continued our fight against HIV & TB epidemics with an investment of $500 million dedicated to R&D and delivery programs

WHO* recommended the use of bedaquiline-containing treatment regimens for all pulmonary drug-resistant TB patients

Launched the first Phase 3 efficacy study of Janssen's investigational HIV preventative vaccine with global partners

Supported Ebola outbreak response in Rwanda and Democratic Republic of Congo by committing to donate up to 700,000 investigational vaccine courses

Completed the first-ever mental health clinical study in Rwanda to help improve access to mental healthcare

Unveiled new Center for Health Worker Innovation to address global health worker shortage

Achieved WHO* prequalification for VERMOX CHEWABLE (mebendazole chewable 500mg tablets) to treat intestinal worms in children and extended commitment to donate up to 1 billion additional doses through 2025

* World Health Organization

Responsible Business Practices

- Launched the J&J Innovation Champions program offering R&D scientists a six-month secondment to an external innovation organization
- 15,000 employees trained in the principles of ENERGY FOR PERFORMANCE

Employees in our Seoul office participating in a group yoga class.

- 30% of our electricity is produced or procured from renewable energy sources
- 32% reduction in CO₂ emissions since 2010

Environmental Health

- Signed 4 new power purchase agreements, significantly advancing progress toward our 100% renewable electricity goal
- Received CDP Climate Change and Water Security A List ratings for leadership in environmental transparency and performance

43% of Manager and above talent movement that was across function, country or business segment lines**

#1 on Gartner's 2019 Healthcare Supply Chain Top 25 list

46% of management roles held by women

$1.6 billion spend with diverse suppliers

** Represents the proportion of employees in Manager and above job categories who in their career progression movement (including upward promotion, downward demotion, or lateral transfer) crossed function, country or business segment lines.
You Belong:
Diversity &
Inclusion

Be yourself,
change the world
Our Fundamental Principles

Drive both performance and purpose with equal commitment

The most broadly-based health care company in the industry

Unparalleled scientific expertise and innovation

World-class talent and capabilities
Agenda

1. Sustainability Governance
2. Strategic Ethics & Compliance Overview
3. Environmental Sustainability
4. Update from the Office of the Chief Medical Officer
5. Quality & Compliance
6. Global Public Health
7. Q&A
Cautionary Note on Forward-looking Statements

This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to our business, or on our ability to execute business continuity plans, as a result of the COVID-19 pandemic; economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” in the company’s most recently filed Quarterly Report on Form 10-Q and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this presentation speaks only as of the date of this presentation. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Cautionary Note on Non-GAAP Financial Measures

This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the Company's website at www.investor.jnj.com.
During the course of this presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners, licensed from other companies, or funded by governmental or non-profit organizations. Following is an acknowledgement of those relationships:

### Oncology
ERLEADA is licensed from The Regents of California and Memorial Sloan Kettering Cancer Center

### Neuroscience
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA includes technology licensed from Alkermes Pharma Ireland Limited

### Infectious Diseases & Vaccines
COMPLERA / EVIPLERA, ODEFSEY, SYMTUZA, PREZEMP / REZOLSTA fixed-dose combination products developed in collaboration with Gilead Sciences, Inc.; JULUCA developed and marketed in collaboration with ViV Healthcare Ltd.; Long acting HIV injectable treatment regimen of rilpivirine and cabotegravir developed in collaboration with ViV Healthcare Ltd.; JSC Pharmstandard manufactures and distributes SIRTURO in Russia and other countries in the region, including the Commonwealth of Independent States (CIS); Since 2005, Janssen Vaccines & Prevention B.V. has been participating in the NIH-supported Integrated Precinical/Clinical AIDS Vaccine Development (IPCAVD) program under grants AI066305, A078526 and AI096040, in collaboration with Professor Dan Barouch at Beth Israel Deaconess Medical Center (BIDMC); Janssen’s HIV vaccine program has also received funding or support from the United States Military HIV Research Program (MHRP) at the Walter Reed Army Institute of Research (WRAIR), with the Henry M. Jackson Foundation for the Advancement of Military Medicine (HMF); the Ragon Institute; and the International AIDS Vaccine Initiative (IAVI); The phase 2b proof-of-concept efficacy study Imbokodo (HVTN 705/HPX2008) for the HIV prophylactic vaccine received co-funding from two primary partners, the Bill & Melinda Gates Foundation and National Institute of Allergy and Infectious Diseases (NIAID). Additional partners providing support include the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research, U.S. Army Medical Materiel Development Activity, and the Ragon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT) and Harvard. The study is conducted at clinical sites coordinated by the NIAID-funded HIV Vaccine Trials Network (HVTN). The South African Medical Research Council (SAMRC) is helping to implement HVTN 705/HPX2008 in South Africa; License and collaboration agreements with Bavarian Nordic to leverage their MVA-BN technology with Janssen’s own ADVAC and DNA-based vaccine technologies in the development and commercialization of potential new vaccine regimens against hepatitis B virus (HBV) and the human immunodeficiency virus (HIV-1); Zika vaccine in collaboration with Beth Israel Deaconess Medical Center (Harvard School); License and collaboration agreement with GSK (Glycovaxyn) for the development of ExPEC.

### Global Public Health
Janssen’s Monovalent Ebola Vaccine is developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S. The program has benefited from funding and preclinical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, NIAID support included 2 product development contracts starting in 2008 and 8 pre-clinical services contracts. This program is also receiving funding from the IM2 Joint Undertaking under EBOVAC2 (grant nr. 115861), EBOVAC2 (grant nr. 115861), EBOVAC2 (grant nr. 115861), and EBOVAC2 (grant nr. 115861). The IM2 Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Further funding for the Ebola vaccine regimen has been provided by the BARDA, within the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, under Contract Numbers HHS0102017000136C and HHS0102021500008C. The initial work on Ebola was conducted which was extended from 2002 until 2011. 2002 and 2007 via a Cooperative Research and Development Agreement (CRADA is AI-0114) between Janssen/Crucell and the Vaccine Research Center (VRC)/NIAID, part of the NIH. Janssen/Crucell have licenses to much of VRC’s Ebola IP specific for human adenovirus under the Ad26/Ad35 Ebola vaccine CRADA invention. VAC69120 (Filovirus multivalent vaccine) developed in collaboration with Bavarian Nordic; funding: NIH Division of Microbiology and Infectious Diseases (DMID), under Contract Number HHSN272200800056C.
Sustainability Governance

Dirk Brinckman
Worldwide Vice President, Global Regulatory Law, Supply Chain & Procurement
Our Credo informs our approach to long-term value creation
Our Priority Topics Assessment informs our reporting, disclosure and goal setting

- Better health for all
- Responsible business practices
- Environmental health
Reporting and disclosure

2019 Health for Humanity Report

Sustainability Accounting Standards Board (SASB) Index
Reporting and disclosure

2019 Health for Humanity Report

Sustainability Accounting Standards Board (SASB) index

External assurance
Reporting and disclosure

- 2019 Health for Humanity Report
- Sustainability Accounting Standards Board (SASB) index
- External assurance
- Policies and positions
Robust ESG governance
Robust ESG governance

- Governance structure
- Board of Directors’ oversight
Robust ESG governance

- Governance structure
- Board of Directors’ oversight
- Enterprise risk management
Robust ESG governance

- Governance structure
- Board of Directors’ oversight
- Enterprise risk management

Enterprise Risk Management Framework
Robust ESG governance

- Governance structure
- Board of Directors’ oversight
- Enterprise risk management
- Enterprise Governance Council
Our Credo and culture

We believe our first responsibility is to the patients, doctors and nurses, to mothers and fathers and all others who use our products and services.

- Values guide our decision-making and put the needs and well-being of the people we serve first
- Compliance program is focused on prevention
Our approach to compliance

- **Prevent**
  - Dedicated compliance teams for each business sector

- **Detect**
  - Global cross-segment support from the Anti-Corruption Program Office, Global Operations team, Global Audit & Assurance group and Investigations

- **Correct**
  - Provides consistency and knowledge sharing, allows customized programs to meet sector-specific needs and risks
Prevent

Clear policies and guidance

Sector compliance committees at the local and regional levels

Board and management oversight and engagement

Robust training and education

Consistent communications and tone at the top

Performance incentives aligned with compliance expectations

Independent compliance organization that is properly resourced
Detect

- Robust data analytics and monitoring
- Continuous risk assessment
- Third party due diligence and monitoring
- Multiple reporting options
- Independent audits and assessments
Thorough investigations

Discipline, including termination, for violations

Management action plans (corrective actions)

- Risk assessment findings
- Audit findings
- Sensitive issue investigation findings
Environmental Sustainability

Paulette Frank
Vice President, Environmental Health, Safety & Sustainability
We continue to make solid progress against our environmental Health for Humanity 2020 Goals

Integrate sustainable design into product innovation

22% Johnson & Johnson revenue from EARTHWARDS-recognized products; target 20%

Reduce our impacts on climate and water resources

32% Reduction of Scope 1 & 2 CO₂ emissions compared to 2010; target 20%

30% Consumption of renewable electricity; target 35%

100% High-water risk sites with risk mitigation plans in place; target 100%
We continue to demonstrate leadership in climate resilience, water security and supplier engagement.

- Recognized for our **environmental performance and transparency** placing us among the top 2% of companies participating in the CDP survey.
- Recognized with an **EPA Green Power Leadership Award**.
We continue to make progress towards our Consumer Health Global Plastics Commitment

Our targets:

1. **Reduce**
   - Eliminate problematic or unnecessary plastic packaging by 2025

2. **Reuse**
   - Move from single-use towards reuse models where relevant by 2025

3. **Eliminate waste**
   - 100% of plastic packaging to be reusable, recyclable or compostable by 2025

4. **Recycled content**
   - Set an ambitious 2025 post-consumer recycled content target across all plastic packaging used

Key highlights:

- Leadership brands have developed strategic plans to drive progress on recyclability, recycled content and refill models
- Set a 15% target for post consumer recycled content for plastics packaging
- Rolled out an internal Design for Recyclability Policy to guide our packaging design choices
- Invested in partnerships to advance recycling—Materials Recovery for the Future, More Recycling and The Recycling Partnership
2019 Health for Humanity Report:
Update from the Office of the Chief Medical Officer

Joanne Waldstreicher, M.D.
Chief Medical Officer
Johnson & Johnson: a strong legacy of delivering innovative products to improve people’s lives

- **1890s**
  - MATERNITY KITS to make childbirth safer

- **1880s**
  - **1894**
    - First mild & soap-free BABY SHAMPOO
  - **1921**
    - **BAND-AID® BRAND**
      - First commercial dressings for small wounds
  - **1954**
    - **CHARNLEY® HIP**
      - First low-friction hip implant
  - **1967**
    - **HALDOL®**
      - Gold standard for schizophrenia
  - **1962**
    - **TYLENOL®**
      - First prescription aspirin-free pain reliever
  - **1984**
    - **SUNDOWN®**
      - First ever sunscreen introduced in Brazil

- **1990s**
  - **1994**
    - **LCS® TOTAL KNEE SYSTEM**
      - First mobile bearing knee system
  - **1998**
    - **REMICADE®**
      - First biologic for Crohn’s disease
  - **1994**
    - **FIRST AID KITS**
      - First commercial
  - **1987**
    - **CONTACT LENSES**
      - First one-week disposable contact lenses

- **2000s**
  - **2006**
    - **AVEENO®** launches patented formula for UV protection
  - **2011**
    - **TYLENOL®**
      - Provided first Fever Treatment Guide in China
  - **2011**
    - **ZYTIGA®**
      - Treatment for prostate cancer
  - **2013**
    - **IMBRUVICA®**
      - New treatment for B-cell malignancies
  - **2015**
    - **SIRIUS®**
      - First new treatment for MDR-TB in over 40 years
  - **2019**
    - **SPRAVATO™**
      - New mechanism of action to treat major depressive disorder

- **2010s**
  - **2013**
    - **OLYSIO®**
      - New treatment for hepatitis C
  - **2016**
    - **DARZALEX™**
      - First biologic for multiple myeloma
  - **2018**
    - **THERMOCOOL SMARTTOUCH®**
      - First catheter to provide direct & real-time measurement of contact force against heart wall

- **2000**
  - **2005**
    - **COMPEED®**
      - Cold sore patch: First to treat cold sore as wound

- **2004**
  - **2009**
    - **MOTRIN®**
      - Provided first Fever Treatment Guide in China

- **2007**
  - **GENESEARCH BLN**
    - Diagnostic test for early cancer detection

- **1990**
  - **1998**
    - **REMICADE®**
      - First biologic for Crohn’s disease

- **1980**
  - **1984**
    - **HALDOL®**
      - Gold standard for schizophrenia
  - **1987**
    - **CONTACT LENSES**
      - First one-week disposable contact lenses

- **1970**
  - **1988**
    - **FIRST AID KITS**
      - First commercial
  - **1985**
    - **COMPEED®**
      - Cold sore patch: First to treat cold sore as wound

- **1960**
  - **1962**
    - **CHARNLEY® HIP**
      - First low-friction hip implant
  - **1964**
    - **HALDOL®**
      - Gold standard for schizophrenia
  - **1967**
    - **HALDOL®**
      - Gold standard for schizophrenia

- **1950**
  - **1954**
    - **FIRST AID KITS**
      - First commercial
  - **1956**
    - **BAND-AID® BRAND**
      - First commercial dressings for small wounds

- **1940**
  - **1948**
    - **MOTRIN®**
      - Provided first Fever Treatment Guide in China

- **1930**
  - **1939**
    - **CHARNLEY® HIP**
      - First low-friction hip implant

- **1920**
  - **1921**
    - **BAND-AID® BRAND**
      - First commercial dressings for small wounds
  - **1922**
    - **HALDOL®**
      - Gold standard for schizophrenia

- **1910**
  - **1913**
    - **HALDOL®**
      - Gold standard for schizophrenia
  - **1914**
    - **HALDOL®**
      - Gold standard for schizophrenia

- **1900**
  - **1904**
    - **FIRST AID KITS**
      - First commercial
  - **1906**
    - **HALDOL®**
      - Gold standard for schizophrenia
Our Efforts are Guided by Our Credo

Mission: to renew our commitment to patients and consumers

• Working in the tradition of Credo-based leadership
• Focusing the enterprise on patients and consumers
• Evidence- and science-based; ethics and values-driven
• Independent and objective safety management
Johnson & Johnson’s Office of the Chief Medical Officer

A global, functionally independent group responsible for leading medical safety and championing bioethical principles across Johnson & Johnson’s Pharmaceuticals, Medical Devices and Consumer Health sectors.

- Advancing evidence- and science-based decision-making
- Guided by a single medical safety standard

Responsibilities of the OCMO:

- Medical Safety
- Epidemiology & Health Informatics
- Bioethics and Scientific Policy
- Clinical, Regulatory & Planning Ops Transformation
- Objective, Expert Pipeline & Product Review
- Translational Science and Safety
J&J’s efforts to combat COVID-19
Bioethical decision-making during the COVID-19 global pandemic

Obligation to allocate our resources fairly and responsibly and aim to save as many lives as possible

Ethics-based framework, consistent with our Credo, that guides how we will allocate supply of our products

Collaborated with internal and external experts to develop an ethics-based framework for decision-making during the COVID-19 pandemic
Our priority:
Allocate our resources fairly and responsibly with the aim to save as many lives as possible and reach as many patients who need it most.

J&J bioethical framework in response to COVID-19

1. Commitment to standing by those patients who are already using our medicines and products and receiving important, sometimes life-saving benefits

2. Supply for well-designed randomized clinical trials that will provide important safety and efficacy data to inform clinical practice

3. Supply studies or registries that are not designed as randomized clinical trials but may collect and share valuable information
Compassionate Use Advisory Committee

Novel approach for reviewing requests for Janssen’s investigational medicines through a panel of external experts convened by the New York University School of Medicine Division of Medical Ethics

Reviewing requests for investigational medicines

1. Made up of internationally recognized medical experts, bioethicists and patient representatives

2. Nearly 5,000 patients have received access to investigational medicines through our compassionate use platform since November 2015

3. 2019 Recipient of the Reagan-Udall Foundation Innovation Award
Together, we will advance science and medical care.

Together, we will make a difference in the world.
Quality & Compliance

Carol Montandon
Chief Quality Officer
We believe our first responsibility is to the patients, doctors and nurses, to mothers and fathers and all others who use our products and services. In meeting their needs **everything we do must be of high quality.**
Continuing to drive improvement in overall quality

New position on Quality & Compliance outlines our proactive quality management approach, which drives end-to-end quality excellence across all stages of a product lifecycle.

Leadership Imperatives were refreshed to ensure we are equipped to lead well into the future.

The Imperatives address how we’re going to profoundly change human health.
Quality metrics
2019 Performance

521*
# of worldwide health authority inspections of J&J sites

73%*
Percentage that resulted in zero observations

Product Recall Rates

0.002%
Pharmaceutical

0.041%
Medical Devices

0.091%
Consumer Health OTC

7 Year Recall Trend

78% Reduction¹

¹ Source: Internal Data

* Data has been assured by PricewaterhouseCoopers LLP (PwC)
Making an impact around the world

- Deployment of Smart Glasses to mitigate the inability to be onsite
- Leveraging robots to assist in remote execution of audits
- Disinfecting N95 masks for healthcare worker re-use
- Production of hand sanitizer at nine J&J manufacturing facilities
- Reimagined quality framework to drive innovative clinical trial approaches
At J&J, we have anticipated the global health challenges facing humanity for over 134 years

For the next decade the WHO has identified 13 urgent health challenges

- Climate Crisis
- Health in Crisis & Conflict
- Accessible healthcare for everyone
- Expanding access to medicines
- Fighting communicable diseases
- Preparing for epidemics
- Making healthy food more accessible
- Investing in health care workers
- Promoting adolescent safety
- Strengthening trust with public
- Utilizing modern technology & innovation
- Preventing antibiotic resistance
- Ensuring facilities are clean & sterile

World Health Organization, Urgent health challenges for the next decade. Published January 13, 2020
Note: The challenges are not listed in order of priority. All are urgent, and many are interlinked.
We established a Global Public Health organization to address the most pressing and urgent threats.

A team of innovators who put the world’s most vulnerable and underserved at the heart of everything we do—measuring our success in lives improved.

End-to-end Organization

- Research & Development
- Strategy & External Affairs
- Field-based teams

Execute with the full capabilities & resources of Johnson & Johnson

100+ partners helping to enable and sustain impact

110 million+ lives positively impacted in resource-limited settings today
We deliver impact from the lab to the last mile by:

- Enabling, advancing & unlocking breakthrough science for global health challenges
- Developing holistic and impactful solutions to ensure innovations are available, affordable and accessible
- Focusing, convening and advocating to move the world’s health forward, faster
By focusing on tackling the highest unmet needs we are able to co-create and deliver sustainable health solutions that maximize our impact.
We expanded access for patients, created a pathway to end drug-resistant TB and made significant R&D commitment

- Expanded regulatory approvals for bedaquiline to 63 countries, including the 30 highest-burden countries
- Committed $500 Million investment over four years to help end HIV & TB; established several international consortia to advance pioneering TB science
- Secured U.S. FDA approval for adolescent and pediatric indications for bedaquiline

- 188,000 patients treated cumulatively with a bedaquiline-containing regimen between 2012-2019
- New WHO guidelines established bedaquiline as back-bone for DR-TB regimen
- Strengthened health systems capacity by training health workers, improving diagnostic capacity, and supporting efforts to ensure appropriate use

- Supported Economist Intelligence Unit to develop case for action to end DR-TB—repositioning it as the winnable battle in AMR
- Re-launched Private Sector Constituency of Stop TB to engage industry in fight
- First-of-its-kind partnership with MTV Staying Alive Foundation to raise awareness of TB in India
We made significant progress to prevent and respond to Ebola and other pandemic threats

1. Enable, advance and unlock breakthrough science for global health challenges

2. Develop holistic and impactful solutions to ensure innovations are available, affordable and accessible

3. Focus, convene and advocate to move the world’s health forward, faster

- Recently granted CHMP positive opinion for investigational Ebola vaccine regimen which leverages Johnson & Johnson’s AdVac® and Per.C6® vaccine technology
- Set up large-scale clinical study in Democratic Republic of Congo for Ebola vaccine; received emergency use approval from Government of Rwanda
- Assessed potential of candidate Zika preventive vaccine, which showed acceptable safety and clear immunogenicity in a 2019 Phase 1 trial
- Committed up to 700,000 Ebola vaccine regimens to the Democratic Republic of Congo and Rwanda to support containment efforts for ongoing Ebola outbreak
- Deployed novel iris scanning technology to support tracking and monitoring of volunteers in large scale Ebola vaccination program
- As chair and co-founder of the Private Sector Roundtable on Global Health Security signed MOU with Government of Uganda to strengthen their country’s pandemic preparedness
Health for Humanity 2020 Goals Progress:
Deliver innovative healthcare access and training programs that impact a billion lives in underserved areas

<table>
<thead>
<tr>
<th>Target</th>
<th>Progress Against 2020 Targets (Cumulative)</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Produce and donate 1 billion doses of VERMOX (mebendazole) to treat &gt;100 million children per year at risk for intestinal worms**.</td>
<td>0.8 billion doses of VERMOX donated in 42 countries with 415 million children having been targeted for treatment.</td>
<td>ON TRACK</td>
</tr>
<tr>
<td>Deliver access to MDR-TB therapy to a cumulative 200,000 patients, potentially curing* 157,000 people with MDR-TB of the disease.</td>
<td>182,000 patients received access to MDR-TB therapy with SIRTURO (bedaquiline). For 37,000 patients provided access in 2016 and 2017, an estimated 32,000 patients** have been potentially cured based on the 87.8% cure rate.*</td>
<td>ON TRACK</td>
</tr>
<tr>
<td>Deliver HIV/AIDS therapy access to a cumulative 130,000 adults and 5,000 children.</td>
<td>104,000 adult patients and over 700 pediatric patients received access to HIV therapy with the branded and generic versions of PREZISTA (darunavir), INTELENCE (etravirine) and EDURANT (rilpivirine).</td>
<td>IN PROGRESS</td>
</tr>
</tbody>
</table>

* The cure rate is 87.8% for patients treated with bedaquiline-containing regimens, based on The Lancet Respiratory Medicine, Volume 392, September 2018, Pages 821-834.

** As communicated through the product label, SIRTURO is taken for six months as part of a combination therapy with multiple other drugs; in total, a patient often requires up to two years of treatment to be cured.
Public health in the developing world faces enormous challenges that require unique solutions, and by engaging, enabling and empowering local health care professionals and entrepreneurs, we can advance the research, development and distribution of new medicines and treatments that will make a difference for patients.

Alex Gorsky
Chairman, Board of Directors and Chief Executive Officer, Johnson & Johnson
Q&A Panel

Dirk Brinckman
Worldwide Vice President, Global Regulatory Law, Supply Chain & Procurement

Carol Montandon
Chief Quality Officer

Joanne Waldstreicher, M.D.
Chief Medical Officer

Ashley Watson
Chief Compliance Officer

Chris DelOrefice
Vice President, Investor Relations

Kristen Mulholland
Head of Global Total Rewards

Matt Orlando
Corporate Secretary

Adrian Thomas
Vice President, Strategy & External Affairs, Global Public Health
Johnson & Johnson